ClinicalTrials.gg
RecruitingNCT05305872Updated Feb 9, 2024

Gandouling in the Treatment of Wilson's Disease

A Phase 4 interventional study of Gandouling in Wilson's Disease, sponsored by Jun Li. Recruiting at 1 site in China. Open to participants aged 15 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-02-09.

Sponsored by Jun Li · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
15 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Hepatolenticular Degeneration with a site in China — 10 open to participants now, 11 under way, 1 of them phase 3. Hepatolenticular Degeneration · China.

Started
2023
the only one that year
Phase 4
Only one
of the 15
Primary completion
2023-03
later than 1 of 10 live
Registered
7th of 15
by date
Lead sponsor
1 of 15
Jun Li

Among the 15 studies in Hepatolenticular Degeneration with a site in China, this one is the only one that started in 2023, is the only one in phase 4, reaches primary completion later than 1 of the 10 other live ones, and was the 7th registered.

Hepatolenticular Degeneration

80 studies on the registry are indexed under Hepatolenticular Degeneration; 31 are open to participants now.

Browse Hepatolenticular Degeneration studies →

Open to participants now

10 of the 15 studies in Hepatolenticular Degeneration with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 22 Hepatolenticular Degeneration studies recruiting now, 17 (77%) set no upper age limit and 4 (18%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.

This study: 15 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hepatolenticular Degeneration with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of gandouling tablet in the treatment of clinical symptoms of Wilson's diasease.

Read the detailed description

To evaluate the efficacy and safety of gandouling tablet in the treatment of clinical symptoms of Wilson's diasease.Test various indicatorsbefore test, 4 weeks, 12 weeks and 24 weeks.

03

Conditions studied

  • Wilson's Disease
04

Who can participate

Ages eligible
15 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Comply with the diagnosis of Wilson's disease "Guidelines for Diagnosis and Treatment of Wilson's disease 2021"
  • The diagnosis of TCM syndromes complies with the syndrome of phlegm and blood stasis; Other copper-removing drugs
  • Patients who have been treated with complexing agents for copper-removing treatment can enter the study after a 2-week
  • Age ≥15 years
  • of patients or legal representatives, And sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Severe cerebral WD patients: obvious torsion spasm, dysphagia, or bed rest and other severe neurological impairment will interfere with the safety of the subjects (UWDRS Part I neurological function score ≥156 points)
  • Severe liver Type WD patients: Decompensated liver cirrhosis or liver cancer, manifested as portal hypertension, ascites, splenomegaly (WBC\<3.0*109/L, \<50*1012/L), esophageal varices, gastrointestinal bleeding, Moderate to severe anemia or hepatic encephalopathy; severe liver fibrosis shown by imaging or any laboratory abnormality (UWDRS liver function score ≥ 17 points)
  • Moderate to severe depression, recent suicidal thoughts or behavior, Severe psychiatric symptoms (UWDRS Part III Psychiatric Symptom Score ≥ 54 points)
  • History of epileptic seizures within 6 months
  • Complicated with serious diseases such as brain tumors, brain trauma, blood diseases, Cardiogenic diseases, , etc.
  • Nephritis, nephrotic syndrome, or kidney disease stage 3 or more
  • Pregnant, planned pregnancy or breastfeeding women
  • Cognitive dysfunction ≤26 points
  • Those who are currently participating in other clinical trials
  • Cannot comply with the follow-up plan
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Treatment group

    Gandouling

    Drug: Gandouling

  • Placebo comparator
    Control group

    Zinc gluconate

    Drug: Gandouling

Interventions

  • DrugGluconic acidStudies of Gluconic acidGluconic acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The experimental group was given gandouling tablet + zinc gluconate simulant; The course of treatment was 24 weeks.

    Also known as: zinc gluconate

06

What researchers measure

Primary outcomes

  1. Unified Wilson's Disease Rating Scale(UWDRS)

    Unified Wilson's Disease Rating Scale(UWDRS),the minimum is 0, and the maximum value is 320. Higher scores mean a worse outcome.

    Time frame: Baseline, before the study

  2. Unified Wilson's Disease Rating Scale(UWDRS)

    Unified Wilson's Disease Rating Scale(UWDRS). Higher scores mean a worse outcome.

    Time frame: 4 weeks

  3. Unified Wilson's Disease Rating Scale(UWDRS)

    Unified Wilson's Disease Rating Scale(UWDRS).Higher scores mean a worse outcome.

    Time frame: 12 weeks

  4. Unified Wilson's Disease Rating Scale(UWDRS)

    Unified Wilson's Disease Rating Scale(UWDRS).Higher scores mean a worse outcome.

    Time frame: 24 weeks

Secondary outcomes

  1. 24-hour urinary copper

    24-hour urinary copper.Higher scores mean a worse outcome.

    Time frame: Baseline, before the study

  2. 24-hour urinary copper

    24-hour urinary copper.Higher scores mean a worse outcome.

    Time frame: 4 weeks

  3. 24-hour urinary copper

    24-hour urinary copper.Higher scores mean a worse outcome.

    Time frame: 12 weeks

  4. 24-hour urinary copper

    24-hour urinary copper.Higher scores mean a worse outcome.

    Time frame: 24 weeks

  5. non-ceruloplasmin bound copper (NCC)

    non-ceruloplasmin bound copper (NCC).Higher scores mean a worse outcome.

    Time frame: Baseline, before the study

  6. non-ceruloplasmin bound copper (NCC)

    non-ceruloplasmin bound copper (NCC).Higher scores mean a worse outcome.

    Time frame: 4 weeks

  7. non-ceruloplasmin bound copper (NCC)

    non-ceruloplasmin bound copper (NCC).Higher scores mean a worse outcome.

    Time frame: 12 weeks

  8. non-ceruloplasmin bound copper (NCC)

    non-ceruloplasmin bound copper (NCC).Higher scores mean a worse outcome.

    Time frame: 24 weeks

Other outcomes

  1. Global Assessment Scale (GAS)

    Global Assessment Scale (GAS).Higher scores mean a worse outcome.

    Time frame: Baseline, before the study

  2. Global Assessment Scale (GAS)

    Global Assessment Scale (GAS).Higher scores mean a worse outcome.

    Time frame: 4 weeks

  3. Global Assessment Scale (GAS)

    Global Assessment Scale (GAS).Higher scores mean a worse outcome.

    Time frame: 12 weeks

  4. Global Assessment Scale (GAS)

    Global Assessment Scale (GAS).Higher scores mean a worse outcome.

    Time frame: 24 weeks

  5. Short Form-36 Questionnaire (SF-36)

    Short Form-36 Questionnaire (SF-36).Higher scores mean a worse outcome.

    Time frame: Baseline, before the study

  6. Short Form-36 Questionnaire (SF-36)

    Short Form-36 Questionnaire (SF-36).Higher scores mean a worse outcome.

    Time frame: 4 weeks

  7. Short Form-36 Questionnaire (SF-36)

    Short Form-36 Questionnaire (SF-36).Higher scores mean a worse outcome.

    Time frame: 12 weeks

  8. Short Form-36 Questionnaire (SF-36)

    Short Form-36 Questionnaire (SF-36).Higher scores mean a worse outcome.

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
  • Jun Li
    Hefei, Anhui 230037, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Mar 2023, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2021
First posted
Mar 31, 2022
StartActual
Jan 1, 2023
Primary completionActual
Mar 1, 2023
CompletionEst.
Dec 31, 2024
Last update
Feb 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05305872
Lead sponsor
Jun Li
Responsible party
Jun Li (associate chief physician, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine) — Sponsor-investigator
First posted
Mar 31, 2022
Start date
Jan 1, 2023
Primary completion
Mar 1, 2023
Completion
Dec 31, 2024 (estimated)
Last update
Feb 9, 2024

Study contacts

Jun Li, Doctor
Contact
18788899919@163.com
18788899919

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gluconic acid

Start the discussion